[武装冲突中系统和局部静血剂的演变]
I D Gretsov1, M A Dmitriev1, E G Obedkov1
1Kursk State Medical University, Kursk, Russia.
Khirurgiia
|November 25, 2024
概括
创伤性出血的紧急护理需要有效的静血剂和装置. 基于酸盐的产品对局部静血有前途,而现代带在极端条件下大大提高了生存能力.
科学领域:
- 紧急医疗 紧急医疗
- 创伤护理 创伤护理
- 军事医学 军事医学
背景情况:
- 创伤性出血在紧急护理中是一个重大挑战,特别是在广泛的军事冲突中.
- 迫切需要巩固当前关于适用于战斗场景的静血干预措施的知识.
- 在严格的环境中管理严重出血的现有文献需要进行系统审查.
研究的目的:
- 审查和总结有关全身和局部静血剂的现有数据.
- 评估用于在战斗条件下暂时停止出血的设备.
- 为了确定战场创伤最有效的静血策略.
主要方法:
- 科学出版物和临床数据的文献综述.
- 系统性静血剂的分析,包括各种配方.
- 评估局部静血产品,重点关注基托基材料.
- 评估用于暂时控制出血的现代和历史设备.
主要成果:
- 基托为基础的止血剂被认为是局部应用的非常有前途的.
- 系统性静血剂是多样化的,其中许多需要进一步广泛的临床试验.
- 现代带显示出卓越的便利性和有效性,与旧型号相比,在极端条件下显著降低死亡率.
结论:
- 基托基药物代表了创伤局部血液静止的显著进展.
- 进一步的临床研究对于优化系统性静血剂的战斗用途至关重要.
- 先进的带是极端环境中管理严重出血的关键救生工具.
相关概念视频
Introduction to Hemostasis
5.7K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
5.7K
Extrinsic and Intrinsic Pathways of Hemostasis
5.6K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
5.6K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
623
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
623
Disorders of Hemostasis
710
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
710
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Vascular Spasm
1.2K
The vascular phase, also known as vasospasm, is the initial stage of hemostasis, crucial for preventing excessive bleeding when a blood vessel is injured. After a vessel is cut, nerves in the damaged area trigger pain and other sensory impulses. Simultaneously, the smooth muscles in the vessel wall contract, resulting in a vascular spasm. This contraction reduces the vessel's diameter at the injury site, slowing or stopping blood loss through the vessel wall. Vascular spasms typically last...
1.2K


